{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:06:36Z","timestamp":1791230796055,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08448-9","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:43:56Z","timestamp":1781801036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chronic proton pump inhibitor exposure aggravates intestinal injury by impairing intestinal stem cell self-renewal through the microbiota-7-ketolithocholic acid Axis"],"prefix":"10.1186","volume":"24","author":[{"given":"Xinyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-5014","authenticated-orcid":false,"given":"Shengliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"7","key":"8448_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003495-200868070-00004","volume":"68","author":"V Boparai","year":"2008","unstructured":"Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs. 2008;68(7):925\u201347. https:\/\/doi.org\/10.2165\/00003495-200868070-00004.","journal-title":"Drugs"},{"issue":"37","key":"8448_CR2","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.3748\/wjg.v25.i37.5578","volume":"25","author":"BB de Brito","year":"2019","unstructured":"de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. WJG. 2019;25(37):5578\u201389. https:\/\/doi.org\/10.3748\/wjg.v25.i37.5578.","journal-title":"WJG"},{"issue":"4","key":"8448_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.amjmed.2018.12.009","volume":"132","author":"RT Kavitt","year":"2019","unstructured":"Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. Am J Med. 2019;132(4):447\u201356. https:\/\/doi.org\/10.1016\/j.amjmed.2018.12.009.","journal-title":"Am J Med"},{"key":"8448_CR4","doi-asserted-by":"publisher","unstructured":"Yadlapati R, Gyawali CP, Pandolfino JE. CGIT GERD consensus conference participants. AGA clinical Practice Update on the personalized approach to the evaluation and management of GERD: expert review. Clin Gastroenterol Hepatol. 2022: 984\u201394.e1. https:\/\/doi.org\/10.1016\/j.cgh.2022.01.025 20.","DOI":"10.1016\/j.cgh.2022.01.025"},{"issue":"2","key":"8448_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1152\/physrev.00016.2019","volume":"100","author":"AC Engevik","year":"2020","unstructured":"Engevik AC, Kaji I, Goldenring JR. The physiology of the gastric parietal cell. Physiol Rev. 2020;100(2):573\u2013602. https:\/\/doi.org\/10.1152\/physrev.00016.2019.","journal-title":"Physiol Rev"},{"key":"8448_CR6","doi-asserted-by":"publisher","unstructured":"Jenkins D, Modolell I. Proton pump inhibitors. BMJ. 2023;383:e070752. https:\/\/doi.org\/10.1136\/bmj-2022-070752.","DOI":"10.1136\/bmj-2022-070752"},{"issue":"5","key":"8448_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.14309\/ajg.0000000000002714","volume":"119","author":"Q Zhuang","year":"2024","unstructured":"Zhuang Q, Chen S, Zhou X, Jia X, Zhang M, Tan N, et al. Comparative efficacy of P-CAB vs proton pump inhibitors for grade C\/D esophagitis: a systematic review and network meta-analysis. Am Gastroenterol. 2024;119(5):803\u201313. https:\/\/doi.org\/10.14309\/ajg.0000000000002714.","journal-title":"Am. J. Gastroenterol"},{"key":"8448_CR8","doi-asserted-by":"publisher","first-page":"175628482412412","DOI":"10.1177\/17562848241241223","volume":"17","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhang R, Fang Y, Zhao R, Fu Y, Ren P, et al. P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis. Therap Adv Gastroenterol. 2024;17:17562848241241223. https:\/\/doi.org\/10.1177\/17562848241241223.","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"8448_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","volume":"57","author":"K Iwakiri","year":"2022","unstructured":"Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267\u201385. https:\/\/doi.org\/10.1007\/s00535-022-01861-z.","journal-title":"J Gastroenterol"},{"issue":"6","key":"8448_CR10","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","volume":"167","author":"A Patel","year":"2024","unstructured":"Patel A, Laine L, Moayyedi P, Wu J. AGA clinical Practice Update on integrating potassium-competitive acid blockers into clinical Practice: expert review. Gastroenterology. 2024;167(6):1228\u201338. https:\/\/doi.org\/10.1053\/j.gastro.2024.06.038.","journal-title":"Gastroenterology"},{"key":"8448_CR11","doi-asserted-by":"publisher","unstructured":"Xia B, He Q, Smith FG, Gkoutos VG, Nirantharakumar K, Kuo ZC, et al. Individualized prevention of proton pump inhibitor related adverse events by risk stratification. In: Nat Commun [Internet]. 15. Nature Publishing Group; 2024. p. 3591. 2025 Mar 14. https:\/\/doi.org\/10.1038\/s41467-024-48007-8.","DOI":"10.1038\/s41467-024-48007-8"},{"issue":"1","key":"8448_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1053\/j.ajkd.2010.03.013","volume":"56","author":"G Regolisti","year":"2010","unstructured":"Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010;56(1):168\u201374. https:\/\/doi.org\/10.1053\/j.ajkd.2010.03.013.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"8448_CR13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/ijerph16091571","volume":"16","author":"BKS Thong","year":"2019","unstructured":"Thong BKS, Ima-Nirwana S, Chin K-Y. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. IJERPH. 2019;16(9):1571. https:\/\/doi.org\/10.3390\/ijerph16091571.","journal-title":"IJERPH"},{"issue":"10","key":"8448_CR14","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.mayocp.2021.02.025","volume":"96","author":"EJ Bell","year":"2021","unstructured":"Bell EJ, Bielinski SJ, St Sauver JL, Chen LY, Rooney MR, Larson NB, et al. Association of proton pump inhibitors with higher risk of cardiovascular disease and heart failure. Mayo Clin Proc. 2021;96(10):2540\u201349. https:\/\/doi.org\/10.1016\/j.mayocp.2021.02.025.","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"8448_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/archinternmed.2010.89","volume":"170","author":"MD Howell","year":"2010","unstructured":"Howell MD, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784\u201390. https:\/\/doi.org\/10.1001\/archinternmed.2010.89.","journal-title":"Arch Intern Med"},{"issue":"4","key":"8448_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/infdis\/jiv184","volume":"212","author":"Y-P Hung","year":"2015","unstructured":"Hung Y-P, Ko W-C, Chou P-H, Chen Y-H, Lin H-J, Liu Y-H, et al. Proton-pump inhibitor exposure aggravates Clostridium difficile \u2013associated Colitis: evidence from a mouse model. J Infect Dis [Internet]. 2015 [cited 2023 Sept 1]; 212(4):654\u201363. https:\/\/doi.org\/10.1093\/infdis\/jiv184.","journal-title":"The J Infect Dis"},{"issue":"4","key":"8448_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jmii.2018.09.002","volume":"53","author":"T-H Chang","year":"2020","unstructured":"Chang T-H, Hsu W-Y, Yang T-I, Lu C-Y, Hsueh P-R, Chen J-M, et al. Increased age and proton pump inhibitors are associated with severe Clostridium difficile infections in children. J Microbiol Immunol Infect. 2020;53(4):578\u201384. https:\/\/doi.org\/10.1016\/j.jmii.2018.09.002.","journal-title":"J Microbiol Immunol Infect"},{"issue":"11\u201312","key":"8448_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/j.1365-2036.2011.04874.x","volume":"34","author":"C Bavishi","year":"2011","unstructured":"Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11\u201312):1269\u201381. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04874.x.","journal-title":"Aliment. Pharmacol. Ther"},{"issue":"4","key":"8448_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/ecco-jcc\/jjac168","volume":"17","author":"M Nighot","year":"2023","unstructured":"Nighot M, Liao P-L, Morris N, McCarthy D, Dharmaprakash V, Ullah Khan I, et al. Long-term use of proton pump inhibitors disrupts intestinal tight junction barrier and exaggerates experimental Colitis. J Crohns Colitis [Internet]. 2023 [cited 2023 Sept 1]; 17(4):565\u201379. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac168.","journal-title":"J Crohns Colitis"},{"key":"8448_CR20","doi-asserted-by":"publisher","unstructured":"Takashima S, Tanaka F, Kawaguchi Y, Usui Y, Fujimoto K, Nadatani Y, et al. Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice. Neurogastroenterology Motil [Internet]. 2020;32(7):e13841. https:\/\/doi.org\/10.1111\/nmo.13841. 2023 Aug 31.","DOI":"10.1111\/nmo.13841"},{"issue":"21","key":"8448_CR21","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3748\/wjg.v30.i21.2751","volume":"30","author":"Y Liang","year":"2024","unstructured":"Liang Y, Meng Z, Ding X-L, Jiang M. Effects of proton pump inhibitors on inflammatory bowel disease: an updated review. World J Gastroenterol [Internet]. 2024;30(21):2751\u201362. https:\/\/doi.org\/10.3748\/wjg.v30.i21.2751. 2025 Apr 4.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"8448_CR22","doi-asserted-by":"publisher","first-page":"2198775","DOI":"10.1080\/07853890.2023.2198775","volume":"55","author":"T Choden","year":"2023","unstructured":"Choden T, Zhang H, Sakuraba A. Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease. Ann Med. 2023;55(1):2198775. https:\/\/doi.org\/10.1080\/07853890.2023.2198775.","journal-title":"Ann Med"},{"key":"8448_CR23","doi-asserted-by":"publisher","unstructured":"Onwuzo S, Boustany A, Khaled Abou Zeid H, Hitawala A, Almomani A, Onwuzo C, et al. Prevalence and risk factors associated with inflammatory bowel disease in patients using proton-pump inhibitors: a population-based study. Cureus [Internet]. [cited 2024 Apr 18], 15, e34088. 2023. https:\/\/doi.org\/10.7759\/cureus.34088.","DOI":"10.7759\/cureus.34088"},{"issue":"11","key":"8448_CR24","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1136\/gutjnl-2020-321609","volume":"70","author":"TX Lu","year":"2021","unstructured":"Lu TX, Dapas M, Lin E, Peters T, Sakuraba A. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. Gut. 2021;70(11):2076\u201384. https:\/\/doi.org\/10.1136\/gutjnl-2020-321609.","journal-title":"Gut"},{"issue":"4","key":"8448_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.gastro.2015.06.043","volume":"149","author":"DE Freedberg","year":"2015","unstructured":"Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883\u20135.e9. https:\/\/doi.org\/10.1053\/j.gastro.2015.06.043.","journal-title":"Gastroenterology"},{"key":"8448_CR26","doi-asserted-by":"publisher","unstructured":"Zhu J, Sun C, Li M, Hu G, Zhao X-M, Chen W-H. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial. In: Gut [Internet]. BMJ Publishing Group; 2023. 2023 Dec 11]; https:\/\/doi.org\/10.1136\/gutjnl-2023-330168.","DOI":"10.1136\/gutjnl-2023-330168"},{"issue":"7","key":"8448_CR27","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2016.05.018","volume":"165","author":"GE Kaiko","year":"2016","unstructured":"Kaiko GE, Ryu SH, Koues OI, Collins PL, Solnica-Krezel L, Pearce EJ, et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell. 2016;165(7):1708\u201320. https:\/\/doi.org\/10.1016\/j.cell.2016.05.018.","journal-title":"Cell"},{"issue":"7803","key":"8448_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41586-020-2127-x","volume":"580","author":"R Wang","year":"2020","unstructured":"Wang R, Li H, Wu J, Cai Z-Y, Li B, Ni H, et al. Gut stem cell necroptosis by genome instability triggers bowel inflammation. Nature. 2020;580(7803):386\u201390. https:\/\/doi.org\/10.1038\/s41586-020-2127-x.","journal-title":"Nature"},{"issue":"5","key":"8448_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cell.2019.01.036","volume":"176","author":"T Fu","year":"2019","unstructured":"Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, et al. FXR regulates intestinal cancer stem cell proliferation. Cell. 2019;176(5):1098\u2013112.e18. https:\/\/doi.org\/10.1016\/j.cell.2019.01.036.","journal-title":"Cell"},{"key":"8448_CR30","doi-asserted-by":"publisher","unstructured":"Baghdadi MB, Ayyaz A, Coquenlorge S, Chu B, Kumar S, Streutker C, et al. Enteric glial cell heterogeneity regulates intestinal stem cell niches. In: Cell stem cell [Internet]. 29. Elsevier; 2022. p. 86\u2013100.e6. 2025 June 3. https:\/\/doi.org\/10.1016\/j.stem.2021.10.004.","DOI":"10.1016\/j.stem.2021.10.004"},{"issue":"8","key":"8448_CR31","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/bph.17439","volume":"182","author":"S Faggin","year":"2025","unstructured":"Faggin S, Cerantola S, Caputi V, Tietto A, Stocco E, Bosi A, et al. Toll-like receptor 4 deficiency ameliorates experimental ileitis and enteric neuropathy: involvement of nitrergic and 5-hydroxytryptaminergic neurotransmission. Br J Pharmacol. 2025;182(8):1803\u201322. https:\/\/doi.org\/10.1111\/bph.17439.","journal-title":"Br J Pharmacol"},{"key":"8448_CR32","doi-asserted-by":"publisher","first-page":"120562","DOI":"10.1016\/j.lfs.2022.120562","volume":"301","author":"S Cerantola","year":"2022","unstructured":"Cerantola S, Faggin S, Caputi V, Bosi A, Banfi D, Rambaldo A, et al. Small intestine neuromuscular dysfunction in a mouse model of dextran sulfate sodium-induced ileitis: Involvement of dopaminergic neurotransmission. Life Sci. 2022;301:120562. https:\/\/doi.org\/10.1016\/j.lfs.2022.120562.","journal-title":"Life Sci"},{"key":"8448_CR33","doi-asserted-by":"publisher","unstructured":"Riehl TE, Alvarado D, Ee X, Zuckerman A, Foster L, Kapoor V, et al. Lactobacillus rhamnosus GG protects the intestinal epithelium from radiation injury through release of lipoteichoic acid, macrophage activation and the migration of mesenchymal stem cells. BMJ Publishing Group; 2019. 2025 June 27]; https:\/\/doi.org\/10.1136\/gutjnl-2018-316226.","DOI":"10.1136\/gutjnl-2018-316226"},{"key":"8448_CR34","doi-asserted-by":"publisher","unstructured":"Zhang G, Lian Y, Li Q, Zhou S, Zhang L, Chen L, et al. Vagal pathway activation links chronic stress to decline in intestinal stem cell function. In: Cell stem cell [Internet]. 32. Elsevier; 2025. p. 778\u201394.e10. 2025 June 6. https:\/\/doi.org\/10.1016\/j.stem.2025.02.016.","DOI":"10.1016\/j.stem.2025.02.016"},{"key":"8448_CR35","doi-asserted-by":"publisher","unstructured":"Yuan M, Chen S, Lin Z, Yu R, Chao K, Ye S, et al. ACSS2-mediated histone H4 lysine 12 crotonylation (H4K12cr) alleviates Colitis via enhancing transcription of CLDN7. In: Adv Sci (Weinh). Vol. 12. Weinheim, Baden-Wurttemberg, Germany; 2025. p. e00461. https:\/\/doi.org\/10.1002\/advs.202500461.","DOI":"10.1002\/advs.202500461"},{"issue":"10","key":"8448_CR36","doi-asserted-by":"publisher","first-page":"101558","DOI":"10.1016\/j.jcmgh.2025.101558","volume":"19","author":"R Yu","year":"2025","unstructured":"Yu R, Zhang C, Yuan M, Ye S, Hu T, Chen S, et al. Exercise-induced metabolite N-lactoyl-phenylalanine ameliorates Colitis by inhibiting M1 macrophage polarization via the suppression of the NF-\u03baB signaling pathway. Cellular Mol Gastroenterol Hepatol. 2025;19(10):101558. https:\/\/doi.org\/10.1016\/j.jcmgh.2025.101558.","journal-title":"Cellular Mol Gastroenterol Hepatol"},{"key":"8448_CR37","doi-asserted-by":"publisher","unstructured":"Wu K, Li L, Liu Y, Wang K, Zheng J, Liang H, et al. PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction. BMJ Publishing Group; 2025. 2026 Apr 28]; https:\/\/doi.org\/10.1136\/gutjnl-2024-334562.","DOI":"10.1136\/gutjnl-2024-334562"},{"key":"8448_CR38","doi-asserted-by":"publisher","unstructured":"Xie L-W, Cai S, Lu H-Y, Tang F-L, Zhu R-Q, Tian Y, et al. Microbiota-derived I3A protects the intestine against radiation injury by activating AhR\/IL-10\/Wnt signaling and enhancing the abundance of probiotics. Gut Microbes [Internet]. [16(1):2347722. https:\/\/doi.org\/10.1080\/19490976.2024.2347722. 2024 Oct 14.","DOI":"10.1080\/19490976.2024.2347722"},{"issue":"1","key":"8448_CR39","doi-asserted-by":"publisher","first-page":"2353399","DOI":"10.1080\/19490976.2024.2353399","volume":"16","author":"H Wu","year":"2024","unstructured":"Wu H, Mu C, Xu L, Yu K, Shen L, Zhu W. Host-microbiota interaction in intestinal stem cell homeostasis. Gut Microbes. 2024;16(1):2353399. https:\/\/doi.org\/10.1080\/19490976.2024.2353399.","journal-title":"Gut Microbes"},{"issue":"7","key":"8448_CR40","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/gutjnl-2023-330883","volume":"73","author":"X Xiao","year":"2024","unstructured":"Xiao X, Zhang X, Wang J, Liu Y, Yan H, Xing X, et al. Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study. Gut. 2024;73(7):1098\u2013109. https:\/\/doi.org\/10.1136\/gutjnl-2023-330883.","journal-title":"Gut"},{"key":"8448_CR41","doi-asserted-by":"publisher","unstructured":"de Vienne Dm, de Vienne DM. Lifemap: exploring the entire tree of Life. PLoS Biol. 2016;14(12):e2001624. https:\/\/doi.org\/10.1371\/journal.pbio.2001624.","DOI":"10.1371\/journal.pbio.2001624"},{"key":"8448_CR42","doi-asserted-by":"publisher","unstructured":"Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. In: Journal of lipid research [Internet]. 47. Elsevier; 2006. p. 241\u201359. 2025 Apr 4. https:\/\/doi.org\/10.1194\/jlr.R500013-JLR200.","DOI":"10.1194\/jlr.R500013-JLR200"},{"key":"8448_CR43","doi-asserted-by":"publisher","first-page":"154457","DOI":"10.1016\/j.metabol.2020.154457","volume":"116","author":"N Nimer","year":"2021","unstructured":"Nimer N, Choucair I, Wang Z, Nemet I, Li L, Gukasyan J, et al. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism. 2021;116:154457. https:\/\/doi.org\/10.1016\/j.metabol.2020.154457.","journal-title":"Metabolism"},{"issue":"2","key":"8448_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.chom.2023.12.015","volume":"32","author":"T Li","year":"2024","unstructured":"Li T, Ding N, Guo H, Hua R, Lin Z, Tian H, et al. A gut microbiota-bile acid axis promotes intestinal homeostasis upon aspirin-mediated damage. Cell Host Microbe. 2024;32(2):191\u2013208.e9. https:\/\/doi.org\/10.1016\/j.chom.2023.12.015.","journal-title":"Cell Host Microbe"},{"issue":"11","key":"8448_CR45","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.3390\/ijms23116046","volume":"23","author":"T Katafuchi","year":"2022","unstructured":"Katafuchi T, Makishima M. Molecular basis of bile acid-FXR-FGF15\/19 signaling axis. IJMS. 2022;23(11):6046. https:\/\/doi.org\/10.3390\/ijms23116046.","journal-title":"IJMS"},{"issue":"6","key":"8448_CR46","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1053\/j.gastro.2021.08.005","volume":"161","author":"B Xia","year":"2021","unstructured":"Xia B, Yang M, Nguyen LH, He Q, Zhen J, Yu Y, et al. Regular use of proton pump inhibitor and the risk of inflammatory bowel disease: pooled analysis of 3 prospective cohorts. Gastroenterology. 2021;161(6):1842\u201352.e10. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.005.","journal-title":"Gastroenterology"},{"issue":"4","key":"8448_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cll.2014.08.008","volume":"34","author":"DE Freedberg","year":"2014","unstructured":"Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med [Internet]. 2014;34(4):771\u201385. https:\/\/doi.org\/10.1016\/j.cll.2014.08.008. 2023 Dec 24.","journal-title":"Clin Lab Med"},{"key":"8448_CR48","doi-asserted-by":"publisher","unstructured":"Zagato E, Pozzi C, Bertocchi A, Schioppa T, Saccheri F, Guglietta S, et al. Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. In: Nat Microbiol [Internet]. 5. Nature Publishing Group; 2020. p. 511\u201324. 2024 Mar 25. https:\/\/doi.org\/10.1038\/s41564-019-0649-5.","DOI":"10.1038\/s41564-019-0649-5"},{"key":"8448_CR49","doi-asserted-by":"publisher","unstructured":"Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. In: Gut [Internet]. 65. BMJ Publishing Group; 2016. p. 749\u201356. 2024 Apr 5. https:\/\/doi.org\/10.1136\/gutjnl-2015-310861.","DOI":"10.1136\/gutjnl-2015-310861"},{"issue":"9","key":"8448_CR50","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.chom.2022.07.015","volume":"30","author":"YG Cao","year":"2022","unstructured":"Cao YG, Bae S, Villarreal J, Moy M, Chun E, Michaud M, et al. Faecalibaculum rodentium remodels retinoic acid signaling to govern eosinophil-dependent intestinal epithelial homeostasis. Cell Host Microbe. 2022;30(9):1295\u2013310.e8. https:\/\/doi.org\/10.1016\/j.chom.2022.07.015.","journal-title":"Cell Host Microbe"},{"issue":"3","key":"8448_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.gendis.2022.09.006","volume":"10","author":"X Dong","year":"2023","unstructured":"Dong X, Cai C, Fu T. FXR suppresses colorectal cancer by inhibiting the Wnt\/\u03b2-catenin pathway via activation of TLE3. Genes & Dis. 2023;10(3):719\u201322. https:\/\/doi.org\/10.1016\/j.gendis.2022.09.006.","journal-title":"Genes & Dis"},{"issue":"8","key":"8448_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-02819-w","volume":"11","author":"J Yu","year":"2020","unstructured":"Yu J, Li S, Guo J, Xu Z, Zheng J, Sun X. Farnesoid X receptor antagonizes Wnt\/\u03b2-catenin signaling in colorectal tumorigenesis. Cell Death Dis [Internet]. Nature Publishing Group; 2020;11(8):1\u201316. https:\/\/doi.org\/10.1038\/s41419-020-02819-w. 2024 Nov 25.","journal-title":"Cell Death Dis"},{"issue":"1","key":"8448_CR53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s43556-021-00035-2","volume":"2","author":"S Girisa","year":"2021","unstructured":"Girisa S, Henamayee S, Parama D, Rana V, Dutta U, Kunnumakkara AB. Targeting farnesoid X receptor (FXR) for developing novel therapeutics against cancer. Mol Biomed. 2021;2(1):21. https:\/\/doi.org\/10.1186\/s43556-021-00035-2.","journal-title":"Mol Biomed"},{"issue":"1","key":"8448_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1124\/jpet.111.179390","volume":"338","author":"A Wolfe","year":"2011","unstructured":"Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, Apte U. Increased activation of the Wnt\/\u03b2-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther. 2011;338(1):12\u201321. https:\/\/doi.org\/10.1124\/jpet.111.179390.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"8448_CR55","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.1038\/ncomms10166","volume":"6","author":"C Jiang","year":"2015","unstructured":"Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015;6(1):10166. https:\/\/doi.org\/10.1038\/ncomms10166.","journal-title":"Nat Commun"},{"issue":"10","key":"8448_CR56","doi-asserted-by":"publisher","first-page":"11235","DOI":"10.1096\/fj.201900839R","volume":"33","author":"LMM Gommers","year":"2019","unstructured":"Gommers LMM, Ederveen THA, van der Wijst J, Overmars-Bos C, Kortman GAM, Boekhorst J, et al. Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI-induced hypomagnesemia. FASEB J [Internet]. 2019;33(10):11235\u201346. https:\/\/doi.org\/10.1096\/fj.201900839R. 2026 Apr 18.","journal-title":"FASEB J [Internet]"},{"issue":"50","key":"8448_CR57","doi-asserted-by":"publisher","first-page":"18129","DOI":"10.1073\/pnas.0505256102","volume":"102","author":"J Wehkamp","year":"2005","unstructured":"Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, et al. Reduced Paneth cell \u03b1-defensins in ileal Crohn\u2019s disease. Proc Natl Acad Sci USA. 2005;102(50):18129\u201334. https:\/\/doi.org\/10.1073\/pnas.0505256102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"8448_CR58","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/gut.2007.142588","volume":"57","author":"LA Simms","year":"2008","unstructured":"Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced \u03b1-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn\u2019s disease. Gut. 2008;57(7):903\u201310. https:\/\/doi.org\/10.1136\/gut.2007.142588.","journal-title":"Gut"},{"issue":"4","key":"8448_CR59","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1189\/jlb.0904543","volume":"77","author":"J Wehkamp","year":"2004","unstructured":"Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn\u2019s disease. J Leukoc Biol. 2004;77(4):460\u201365. https:\/\/doi.org\/10.1189\/jlb.0904543.","journal-title":"J Leukoc Biol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08448-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:31:36Z","timestamp":1788139896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08448-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8448"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08448-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal studies were approved by the Laboratory Animal Welfare Ethics Committee of Renji Hospital, Shanghai Jiao Tong University School of Medicine (Approval No. RJ2023-081A). All experiments were performed in accordance with the ARRIVE guidelines and the Chinese national regulations for laboratory animal care and use. This study did not involve human participants, so consent to participate is not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1116"}}